Target intelligence / Profile preview

Vascular calcification (null)

Target
null
Molecular classification
Other
01

Overview

Vascular calcification is a pathological process involving the deposition of calcium salts, mainly hydroxyapatite, in arterial walls. This process is highly regulated biologically and is not simply a passive result of aging or disease[6][5][4]; instead, it involves molecular pathways similar to those in bone formation, with vascular smooth muscle cells adopting osteoblast-like phenotypes and contributing to matrix mineralization[2][6][7]. Vascular calcification is strongly associated with increased cardiovascular risk and is frequently observed in patients with diabetes, atherosclerosis, and chronic kidney disease, as well as those of advanced age[1][3][5]. There is currently no therapy that reverses calcification; treatment focuses on addressing underlying metabolic disorders and risk factors, and on slowing progression using a combination of lifestyle modifications and medication[1][3][8].

Other names
Arterial calcificationArteriosclerosisHardening of the arteriesMedial vascular calcificationIntimal vascular calcification
02

Mechanism of action

Actions are aimed at modulating contributing factors or preventing progression: - Reduction of serum calcium/phosphate - Modulation of inflammatory mediators - Inhibition of vascular smooth muscle cell transdifferentiation to osteoblast-like cells - Inhibition of bone-related signaling pathways (e.g., BMPs, TGF-β, PDGF, Runx2) - Managing underlying risk factors (diabetes, hypertension, CKD)

03

Biological functions

Pathological mineral depositionvascular stiffeningreduction of vessel compliancesecondary promotion of atherosclerotic plaque progressionmodulation of vascular responses
04

Disease associations

Cardiovascular diseaseChronic kidney diseaseDiabetes mellitusAtherosclerosisHypertensionRare hereditary conditions, e.g., idiopathic infantile arterial calcification
05

Safety considerations

Therapeutic reversal is challenging; available drugs may only slow progressionIncreased risk of vascular rupture, heart attack, strokeSevere calcification increases technical difficulty/safety of coronary interventionsCalciphylaxis in CKD patients, with high mortalityVitamin D/Ca modifying drugs can paradoxically worsen calcification in certain conditions
06

Interacting drugs

Calcium channel blockers (CCBs)

5 more in the full profile.

07

Biomarkers

Coronary artery calcium (CAC) scoreSerum calcium and phosphate levelsVascular calcification detected by X-ray, CT, ultrasoundAgatston score (from CAC scan)

Beyond the preview

Go deeper on Vascular calcification (null).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vascular calcification (null).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call